Small conductance SK (Ca) channel blockers, particularly SK (Ca) 2.3 (SK3; SKCa3; hKCa3) channel blockers, have been described in an Acesion Pharma ApS patent as potentially useful for the treatment of arrhythmia.
Slap Pharmaceuticals LLC have identified new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
An Intra-Cellular Therapies Inc. patent describes new 5-HT2A, μ-opioid, and dopamine D1 and D2 receptor ligands reported to be useful for the treatment of neurological disorders.
Alumis Inc. has patented non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, neurological, autoimmune, inflammatory and endocrine disorders.
Dentists at Melbourne, Australia-based 3DSG Pty Ltd. are seeking patent protection for a plug and socket set for use in a mandibular advancement splint set for treating snoring or sleep apnea.
Zomagen Biosciences Ltd. has prepared and tested new NLRP3 inflammasome modulators reported to be useful for the treatment of autoimmune diseases, cardiovascular disorders, inflammatory disorders, liver diseases, lung diseases, metabolic diseases and neurological disorders.
University of California Oakland and University of Copenhagen scientists have jointly developed calcium/calmodulin-dependent protein kinase type II subunit α (CaMK2A) modulators reported to be useful for the treatment of brain injury, narcolepsy, Angelman syndrome, Down syndrome and stroke.
Research at Prelude Therapeutics Inc. has led to the identification of thaizole-pyrimdiine cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of cancer.
A recent Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. patent describes nitrogen-containing heterocyclic derivatives acting as EGFR (del19 mutant) inhibitors and reported to be useful for the treatment of non-small-cell lung cancer.
RSS
